Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1491-1496

  Shih, Pei Shan ^a   Huang, Jin Ding ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A5; DNA; MIDAZOLAM; MIDAZOLAM MALEATE; 1-HYDROXYMETHYLMIDAZOLAM; CYP3A PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INTRON; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ASIAN; BLOOD; COMPARATIVE STUDY; GENETICS; METABOLISM; TAIWAN;

PIERINAE;

AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MALE; MIDAZOLAM; TAIWAN;

EID: 0036892578     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1491     Document Type: Article

References (29)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, and Gelboin HV (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 264:10388-10395.
2. Boobis AR, Edwards RJ, Adams DA, and Davies DS (1996) Dissecting the function of cytochrome P450. Br J Clin Pharmacol 42:81-89.
3. Chou FC, Tzeng SJ, and Huang JD (2001) Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29:1205-1209.
4. Domanski TL, Finta C, Halpert JR, and Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392.
5. Eeckhoudt SL, Desager JP, Horsmans Y, De Winne AJ, and Verbeeck RK (1998) Sensitive assay for midazolam and its metabolite 1′-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. J Chromatogr B 710:165-171.
6. Finta C and Zaphiropoulos PG (2000) The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13-23.
7. Finta C and Zaphiropoulos PG (2002) Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 277:5882-5890.
8. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, and Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331-334.
9. Gorski JC, Hall SD, Jones DR, Vandenbranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
10. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, and Hall SD (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-59.
11. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, and Kamataki T (1993) Gene structure of CYP3A4, an adult-specific from of cytochrome P450 in human livers and its transcriptional control. Eur J Biochem 218:585-595.
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacoenetics 11:773-779.
13. Jounaidi Y, Hyrailles V, Gervot L, and Maurel P (1996) Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 221:466-470.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
15. Li AP, Kaminski DL, and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
16. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
17. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: Update on new sequences, gene mapping, accession Nos and nomenclature. Pharmacogenetics 6:1-42.
18. Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, Konings F, and Armstrong M (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415-424.
19. Schuetz JD, Beach DL, and Guzelian PS (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
20. Schuetz EG, Schuetz JD, Mclean Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, and Watlington CO (1992) Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys 294:206-214.
21. Spurr NK, Gough AC, Stevenson K, and Wolf CR (1989) The human cytochrome P450 CYP3A locus: Assignment to chromosome 7q22-qter. Hum Genet 81:171-174.
22. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, and Perkins JD (1994a) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharamcol Exp Ther 271:557-566.
23. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, and Barr DM (1994b) Use of midazolam as a human cytochrome P450 3A probe: 1. In vitro-in vivo correlations in liver transplant patients. J Pharamcol Exp Ther 271:549-556.
24. Wandel C, Böcker RH, Böhrer H, Browne A, Rugheimer E, and Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73:658-661.
25. Wandel C, Böcker RH, Böhrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Water-Sack I, and Martin E (1998) Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 26:110-114.
26. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, and Oscarson M (2001) Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349-1355.
27. Wrighton SA, Brian WR, Sari MA, Iwasaki M, and Guengerich FP (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P-450 A5 (HLp3). Mol Pharmacol 38:207-213.
28. Wrighton SA, Ring BJ, Watkins PB, and Vandenbranden M (1989) Identification of a polymorphism expressed member of the human cytochrome P-450 family. Mol Pharmacol 36:97-105.
29. Yates CR, Zhang W, Song P, Gaber AO, Honaker MR, Kotb M, Alloway RR, and Meibohm DB (2002) Effect of CYP3A5 genotype on cyclosporine disposition: A pilot study. Clin Pharmacol Ther 71:P2.